Why Idexx Laboratories Stock Surged by Almost 15% Today
Key Points
It notched a beat-and-raise third quarter.
It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame.
- 10 stocks we like better than Idexx Laboratories ›
Animal healthcare diagnostics specialist Idexx Laboratories' (NASDAQ: IDXX) stock was an unquestionably healthy investment on Monday. Market players flocked to the company's shares following the release of a fresh set of quarterly earnings. Idexx closed the day nearly 15% higher in value, crushing the 0.2% gain of the S&P 500 index.
Throwing investors a tasty treat
Idexx published its third-quarter figures well before market open that day. The company divulged that its revenue was almost $1.11 billion, up a sturdy 13% from the same period of 2024. Net income according to generally accepted accounting principles (GAAP) rose more sharply, growing by 18% to $274.6 million. On a non-GAAP (adjusted) per-share basis, net income rose 15% to $3.22.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
The two numbers were sufficiently high to beat the average analyst estimates. The consensus pundit projection for revenue was $1.07 billion, and that for adjusted profitability was $3.14 per share.
In its earnings release, Idexx CEO Jay Mazelsky said the company "made exceptional progress on our innovation-driven growth strategy with strong execution and global customer adoption."
Guidance raised for two key fundamentals
Management clearly believes this will keep the growth engine running, as it raised guidance for both revenue and net income.
For full-year 2025, Idexx now believes it will earn $4.27 billion to $4.3 billion in revenue, and earnings per share (EPS) of $12.81 to $13.01. The bottoms of both of those ranges top the average analyst estimates; for revenue this is under $4.24 billion, and for EPS it's $12.63.
Should you invest $1,000 in Idexx Laboratories right now?
Before you buy stock in Idexx Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Idexx Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $603,392!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,241,236!*
Now, it’s worth noting Stock Advisor’s total average return is 1,072% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Idexx Laboratories. The Motley Fool has a disclosure policy.
Recommended Articles
